Opinion
Video
Author(s):
Experts on prostate cancer discuss the risks, complications, and safety considerations for patients with prostate cancer who are considering radiation therapy.
Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer
Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC